Lenalidomid Aristo (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4‑CRBN E3 ubiquitin ligase complex. This binding changes the complex’s target proteins, leading to degradation of transcription factors such as Ikaros and Aiolos. The result is reduced tumor cell proliferation, increased apoptosis, inhibition of new blood‑vessel formation, and enhanced immune‑cell activity against cancer cells.

The specific dose of Lenalidomid Aristo is determined by the prescribing clinician based on the patient’s diagnosis, disease stage, renal function, and overall health. Healthcare providers follow approved labeling and clinical guidelines to select the appropriate strength and dosing schedule for each individual.

Lenalidomid Aristo is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because it can cause severe fetal harm. Women of child‑bearing potential must use effective contraception. The safety of lenalidomide during breastfeeding has not been established, and nursing mothers should avoid the drug.

To request Lenalidomid Aristo, visit the product page on gnhindia.com, submit an enquiry with the desired quantity, and provide institutional or trade credentials. GNH India’s commercial team will verify eligibility, then respond with pricing, availability, shipping details—including any cold‑chain requirements—and required import documentation.

Lenalidomid Aristo belongs to the immunomodulatory drug class, offering a distinct mechanism from proteasome inhibitors or monoclonal antibodies. Compared with older agents like thalidomide, lenalidomide generally has a more favorable side‑effect profile, especially regarding neuropathy, while maintaining strong anti‑myeloma activity. Choice of therapy depends on patient‑specific factors and prior treatment history.

Lenalidomid Aristo should be stored at ambient temperature, below 25 °C (77 °F). Keep the tablets in the original packaging to protect them from moisture and light. Do not store in bathrooms or near heat sources, and keep out of reach of children.

Lenalidomid Aristo is taken orally, usually with or without food, as directed by the prescriber. The tablets are swallowed whole with a glass of water. Patients should follow the dosing schedule provided by their healthcare professional and not alter the regimen without medical advice.

Serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, severe infections, secondary malignancies, and teratogenic effects leading to birth defects. Patients should be monitored closely for signs of clotting, infection, and any new cancerous lesions, and strict contraception must be used during treatment.

Lenalidomid Aristo should not be used by individuals who are pregnant, planning to become pregnant, or not using reliable contraception. Patients with uncontrolled infections, severe renal or hepatic impairment without appropriate monitoring, or those with known hypersensitivity to lenalidomide or its excipients should avoid the medication.